Detalles de la búsqueda
1.
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Am J Hematol
; 2024 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38800943
2.
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Am J Hematol
; 2024 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38804599
3.
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Haematologica
; 106(6): 1599-1607, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32499241
4.
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.
Biol Blood Marrow Transplant
; 26(4): 798-804, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31756536
5.
Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.
Biol Blood Marrow Transplant
; 25(2): 335-342, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30243581
6.
Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.
Br J Haematol
; 2024 May 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38797530
7.
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
Haematologica
; 104(2): 380-391, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30262560
8.
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.
Biol Blood Marrow Transplant
; 24(5): 930-936, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29339268
9.
Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.
Biol Blood Marrow Transplant
; 23(4): 618-624, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28087456
10.
Cytomegalovirus sinusitis complicated by orbital apex syndrome in an immunocompromised host.
Transpl Infect Dis
; 18(6): 957-959, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27677910
11.
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Biol Blood Marrow Transplant
; 21(12): 2136-2140, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26211987
12.
Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma.
Am J Clin Oncol
; 2024 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38483213
13.
Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.
Biol Blood Marrow Transplant
; 19(2): 260-5, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23073267
14.
Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study.
Br J Haematol
; 160(2): 199-206, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23151215
15.
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Lancet Haematol
; 10(1): e14-e23, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36403579
16.
Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Biol Blood Marrow Transplant
; 18(3): 486-92, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22198542
17.
Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.
Br J Haematol
; 178(5): 816-819, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27292583
18.
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Lancet Oncol
; 12(13): 1195-203, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21962393
19.
Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation.
Transplant Cell Ther
; 28(7): 367.e1-367.e9, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35534000
20.
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.
Blood
; 113(14): 3383-91, 2009 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-19015394